ENTRADA THERAPEUTICS, INC. Deferred Revenue
ENTRADA THERAPEUTICS, INC. (TRDA) had Deferred Revenue of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2026-02-26
- 2025-12-31: Deferred Revenue $0.00.
- 2025-09-30: Deferred Revenue $113.00K.
- 2025-06-30: Deferred Revenue $194.00K.
- 2025-03-31: Deferred Revenue $301.00K.
| Period end | Deferred Revenue |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $113.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $194.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $301.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $6.51M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.96M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $10.35M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $9.41M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $7.71M 10-K · filed 2025-02-27 |
| 2023-09-30 | $10.51M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $95.51M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $89.24M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |